1.Manns MP，Czaja AJ，Gorham JD，et al. Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology，2010，51（6）：2193-2213.

2.Qiu DK，Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinesepatients. J Gastroenterol Hepatol，2003，18（1）：63-67.

3.Oliveira LC，Porta G，Marin ML，et al. Autoimmune hepatitis，HLA and extended haplotypes. Autoimmun Rev，2011，10（4）：189-193.

4.Mells GF，Kaser A，Karlsen TH. Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun，2013，46：41-54.

5.de Boer YS，van Gerven NM，Zwiers A，et al. Dutch Autoimmune HepatitisStudyGroup；LifeLines CohortStudy；Study of Health in Pomerania. Genome-wide association studyidentifies variants associated with autoimmune hepatitis type 1.Gastroenterology，2014，147（2）：443-52.e5.

6.Migita K，Jiuchi Y，Furukawa H，et al. Lack of associationbetween the CARD10 rs6000782 polymorphism and type 1 autoimmune hepatitis in a Japanese population. BMC Res Notes，2015，8：777.

7.曹海龙，王邦茂，张慧，等.抗微生物药物诱导自身免疫性肝炎的汇总分析.中华消化杂志，2012，32（11）：767-768.

8.Zaja AJ. Drug-induced autoimmune—like hepatitis. Dig Dis Scl，2011，56：958-976.

9.Christen U，Hintermann E. Pathogen Infection as a Possible Cause for Autoimmune Hepatitis. International Reviews of Immunology，2014，33：296-313.

10.Christen U. Pathogen infection and autoimmunity. Int Rev Immunol，2014，33（4）：261-265.

11.Hennes EM，Zeniya M，Czaja AJ，et al. Simplified criteria for the diagnosis of autoimmune hepatitis.Hepatology，2008，48（1）：169-176.

12.Christen U. The role of autoantibodies in autoimmune hepatitis type 2.Immunotherapy，2013，5（3）：247-256.

13.Liberal R，Mieli-Vergani G，Vergani D. Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmunity，2013，46：17-24.

14.Hintermann E，Holdener M，Bayer M，et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J Autoimmunity，2011，37（3）：242-253.

15.Rigopoulou EI，Smyk DS，Matthews CE，et al. Epstein-barr virus as a trigger of autoimmune liver diseases. Adv Virol，2012，2012：987471.

16.Zellos A，Spoulou V，Roma-Giannikou E，et al. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler：art of facts or an artifact?Ann Hepatol，2013，12（1）：147-151.

17.Al-Hamoudi WK. Severe autoimmune hepatitis triggered by varicella zoster infection. World J Gastroenterol：WJG，2009，15（8）：1004-1006.

18.Toyoda-Akui M，Yokomori H，Kaneko F，et al. Association of an overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis with cytomegalovirus infection. Int J Gen Med，2011，4：397-402.

19.Hagel S，Bruns T，Herrmann A，et al. Autoimmune hepatitis in an HIV-infected patient：an intriguing association. Int J STD&AIDS，2012，23（6）：448-450.

20.Christen U，Hintermann E，Holdener M，et al. Viral triggers for autoimmunity：is the ‘glass of molecular mimicry’ half full or half empty?J Autoimmunity，2010，34（1）：38-44.

21.Tunccan OG，Tufan A，Telli G，et al. Visceral leishmaniasis mimicking autoimmune hepatitis，primary biliary cirrhosis，and systemic lupus erythematosus overlap. Korean J Parasitol，2012，50（2）：133-136.

22.Matsumura S，Kita H，He XS，et al. Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis. Hepatology，2002，36（5）：1125-1134.

23.金伯泉.细胞和分子免疫学.北京：科学出版社，2001：420-424.

24.Bogdanos DP，Lenzi M，Okamoto M，et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51.Int J Immunopathol Pharmacol，2004，17（1）：83-92.

25.Haggqcist B，Hultman P. Effects of deviating the Th2-response in murine mercury-induced autoimmunity towards a Th1-response. Clin Exp Immunol，2003，134（2）：202-209.

26.Yadav D，Sarvetnick N. Cytokines and autoimmunity：redundancy defines their complex nature. Curr Opin immunol，2003，15（6）：697-703.

27.Yun Ma，Dimitrios P，Bogdanos，et al. Polyclonal T-Cell responses to Cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2.Gastroenterology，2006，130：868-882.

28.Bogdanos DP，Mieli-Vergani G，Vergani D. Virus，liver and autoimmunity. Dig Liver Dis，2000，32（5）：440-446.

29.Liberal R，Longhi MS，Mieli-Vergani G，et al. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol，2011，25（6）：653-664.

30.Sakaguchi S. Regulatory T cells：key controllers of immunologic self-tolerance. Cell，2000，101（5）：455-458.

31.Corthay A. How do regulatory T cells work?Scand J Immunol，2009，70（4）：326-336.

32.Oo YH，Hubscher SG，Adams DH. Autoimmune hepatitis：new paradigms in the pathogenesis，diagnosis，and management. Hepatol Int，2010，4（2）：475-493.

33.Sakaguchi S，Ono M，Setoguchi R，et al. Foxp3+CD4+CD25+natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev，2006，212：8-27.

34.Carrier Y，Yuan J，Kuchroo VK，et al. Th3 cells in peripheral tolerance.Ⅱ.TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J Immunol，2007，178（1）：172-178.

35.Probst-Kepper M，Geffers R，Kroger A，et al. GARP：a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med，2009，13（9B）：3343-3357.

36.Allan SE，Crome SQ，Crellin NK，et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol，2007，19（4）：345-354.

37.Liu W，Putnam AL，Xu-Yu Z，et al. CD127 expression inversely correlateswith FoxP3 and suppressive function of humanCD4+T reg cells. J Exp Med，2006，203（7）：1701-1711.

38.Seddiki N，Santner-Nanan B，Martinson J，et al. Expression of interleukin （IL）-2 and IL-7 receptors discriminates between human regulatory and activatedT cells. J Exp Med，2006，203（7）：1693-1700.

39.Fontenot JD，Rasmussen JP，Williams LM，et al. Regulatory T cell lineage specfication by the forkhead transcription factor foxp3.Immunity，2005，22（3）：329-341.

40.Wang J，Ioan-Facsinay A，van der Voort EI，et al. Transient expression of FOXP3 in human activated nonregulatory CD4+T cells. Eur J Immunol，2007，37（1）：129-138.

41.Longhi MS，Ma Y，Mieli-Vergani G，et al. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun，2010，34（1）：7-14.

42.Longhi MS，Mitry RR，Samyn M，et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology，2009，50（1）：130-142.

43.Longhi MS，Meda F，Wang P，et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology，2008，47（2）：581-591.

44.Longhi MS，Hussain MJ，Kwok WW，et al. Autoantigen-specific regulatory T-cells，a potential tool for immune tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology，2011，53（2）：536-547.

45.Apostolou I，Verginis P，Kretschmer K，et al. Peripherally induced Treg：mode，stability，and role in speciflc tolerance. J Clin Immunol，2008，28（6）：619-624.

46.Oo YH，Weston CJ，Lalor PF，et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol，2010，184（6）：2886-2898.

47.Lennon GP，Bettini M，Burton AR，et al. T cell islet accumulation in type 1 diabetes is a tightly regulated，cellautonomous event. Immunity，2009，31（4）：643-653.

48.Riley JL，June CH，Blazar BR. Human T regulatory cell therapy：take a billion or so and call me in the morning. Immunity，2009，30（5）：656-65.

49.Trzonkowski P，Bieniaszewska M，Juscinska J，et al. Frist-in-men clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clin Immuno，2009，133（1）：22-26.

50.Longhi MS，Meda F，Wang P，et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology，2008，47（2）：581-591.

51.Riley JL，June CH，Blazar BR. Human T regulatory cell therapy：take a billion or so and call me in the morning. Immunity，2009，30（5）：656-665.

52.Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis，2007，66（suppl 3）：ⅲ87-90.

53.Santodomingo-Garzon T，Swain MG. Role of NKT cells in autoimmune liver disease. Autoimmun Rev，2011，10（12）：793-800.

54.Grant CR，Liberal R，Holder BS，et al. Dysfunctional CD39（POS） regulatory Tcellsand aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology，2014，59（3）：1007-1015.

55.Zhao L，Tang Y，You Z，et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One，2011，19；6（4）：e18909.

56.Longhi MS，Ma Y，Mieli-Vergani G，et al. Adaptive immunity in autoimmune hepatitis. Dig Dis，2010，28（1）：63-69.

57.谭建明，周永昌，唐孝达.组织配型技术与临床应用.北京：人民卫生出版社，2002.